

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 April 2024 (11.04.2024)



(10) International Publication Number
WO 2024/074559 A1

(51) International Patent Classification:

A61K 31/4709 (2006.01) *A61K 31/4523* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4184 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2023/077460

(22) International Filing Date:

04 October 2023 (04.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22306483.3 04 October 2022 (04.10.2022) EP

(71) Applicant: GENOSCIENCE PHARMA [FR/FR]; 10 rue d'Iena, 13006 MARSEILLE (FR).

(72) Inventors: **HALFON, Philippe**; 6 Allée du Château, Parc Marveyre, 13008 MARSEILLE (FR). **BESTION, Eloïse**; Les terrasses de Montval, Bât C, 92 Chemin de la Colline St Joseph, 13009 MARSEILLE (FR). **MEZOUAR, Soraya**; 29 Rue de Lissande, La Batarelle Haute, 13014 MARSEILLE (FR). **COURCAMBECK, Jérôme**; 50 Boulevard du Vaisseau, Résidence les Hauts de Mazargues, Bât D5, 13009 MARSEILLE (FR). **MENUT, Agnès**; 58 Avenue des Caillols, Bât A6, 13012 Marseille (FR).

(74) Agent: **SANTARELLI**; Tour Trinity, 1 Bis Esplanade de la Défense, 92035 PARIS LA DEFENSE CEDEX (FR).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS

(57) Abstract: The invention relates to a combination of substituted 2,4 diamino-quinoline compounds and MEK inhibitors, pharmaceutical compositions containing it and its use as a medicament. The invention further relates to a combination of substituted 2,4 diamino-quinoline compounds and MEK inhibitors, for use in the prevention and/or decreasing and/or treatment of liver cancers. The substituted 2,4 diamino-quinoline compounds and MEK inhibitors constituting said combination can be used simultaneously, separately or sequentially.

WO 2024/074559 A1